In provoked VTE with ≥1 enduring risk factor, extending anticoagulation with apixaban reduced symptomatic recurrent VTE at 12 mo

Annals of Internal Medicine 2026

View at publisher

Authors: Andrew S Dunn

DOI: 10.7326/annals-25-04963-jc

Cited by: 0

References: 2

Abstract

CLINICAL IMPACT RATINGS: GIM/FP/GP: [Formula: see text] Hematology: [Formula: see text].

Blood Coagulation and Thrombosis Mechanisms Atrial Fibrillation Management and Outcomes Venous Thromboembolism Diagnosis and Management

References 2